BROWSE·page 199 of 257

Browse EX-10 agreements

3,074 matching material contract exhibits.


EX-10.2

Alignment Healthcare, Inc.

EMPLOYMENT AGREEMENT BETWEEN

ALIGNMENT HEALTHCARE USA, LLC AND

MARK KENT

May 18, 2026


EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT is made and entered into effective as of May 18, 2026 (the “Effective Date”), by and between Alignment Healthcare USA, LLC, a California corporation (the “Employer”), and Mark Kent (the “Employee”).

WHEREAS, the Employer desires to employ the Employee, and the Employee desires to accept such employment, on the terms and subject to the conditions hereinafter set forth.

NOW, THEREFORE, in consideration of the covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows.

1.Definitions. Generally, defined terms used in this Agreement are defined in the first instance in which they appear herein. In addition, the following terms and phrases have the following meanings:

…

EX-10.2·10-Q·CIK 1832466·ACC 0001628280-26-051060·Filed Jul 30, 2026, 16:14 ET

EX-10.1

UNIVERSAL INSURANCE HOLDINGS, INC.

EXECUTION VERSION

J.P. Morgan

CREDIT AGREEMENT

dated as of

May 29, 2026

among

UNIVERSAL INSURANCE HOLDINGS, INC.

The Lenders Party Hereto

JPMORGAN CHASE BANK, N.A.
as Administrative Agent

_______________________________

JPMORGAN CHASE BANK, N.A.
as Sole Bookrunner and Sole Lead Arranger

SECTION 1.01    Defined Terms    1

SECTION 1.02    Classification of Loans and Borrowings    27

SECTION 1.03    Terms Generally    27

SECTION 1.04    Accounting Terms; GAAP; SAP; Pro Forma Calculations    28

SECTION 1.05    Interest Rates; Benchmark Notification    29

SECTION 1.06    Status of Obligations    29

SECTION 1.07    Letter of Credit Amounts    30

…

EX-10.1·10-Q·CIK 891166·ACC 0000891166-26-000088·Filed Jul 30, 2026, 16:11 ET

EX-10.2

AGREE REALTY CORP

AGREE REALTY CORPORATION

2024 OMNIBUS INCENTIVE PLAN

RESTRICTED STOCK UNIT NOTICE

This RESTRICTED STOCK UNIT NOTICE dated as of _________, 20__, sets forth the terms of a grant of Restricted Stock Units by Agree Realty Corporation, a Maryland corporation (the “Company”), to the Grantee named below.

WHEREAS, the Company has adopted the Agree Realty Corporation 2024 Omnibus Incentive Plan (the “Plan”) to provide incentives and awards to employees, directors and consultants of the Company and its Affiliates, by encouraging their ownership of stock and to aid the Company and its Affiliates in retaining such employees, directors and consultants, upon whose efforts the Company’s success and future growth depends, and attracting other such individuals;

WHEREAS, the Company has adopted the Agree Realty Corporation Director Restricted Stock Unit Program (the “RSU Program”); and

WHEREAS, under the RSU Program, the Grantee has elected to receive an award of Restricted Stock Units (the “Award”) as provided herein.

…

EX-10.2·10-Q·CIK 917251·ACC 0000917251-26-000063·Filed Jul 30, 2026, 16:10 ET

EX-10.1

AGREE REALTY CORP

AGREE REALTY CORPORATION

DIRECTOR RESTRICTED STOCK UNIT PROGRAM

1. Adoption and Effective Date. Effective as of March 6, 2026 (the “Effective Date”), Agree Realty Corporation, a Maryland corporation (the “Company”) has adopted the Director Restricted Stock Unit Program (the “RSU Program”) to permit members of the Board of Directors of the Company (the “Board”) to elect to receive their annual equity grant in the form of restricted stock or restricted stock units, as described herein. Capitalized terms not defined herein shall have the meaning ascribed to them in the Plan, unless the context requires otherwise.

2. Eligible Participants. Participation in the RSU Program is limited to members of the Board of Directors of the Company (each, a “Director”).

…

EX-10.1·10-Q·CIK 917251·ACC 0000917251-26-000063·Filed Jul 30, 2026, 16:10 ET

EX-10.1

CASTLE BIOSCIENCES INC

Castle Biosciences, Inc.

Non-Employee Director Compensation Policy

Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “DirectorCompensation Policy”) for his or her Board service. A Non-Employee Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be.

This Director Compensation Policy is effective as of May 28, 2026 (the “Effective Date”), and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

Annual Cash Compensation

…

EX-10.1·10-Q·CIK 1447362·ACC 0001628280-26-051052·Filed Jul 30, 2026, 16:09 ET

EX-10.2

Grand Canyon Education, Inc.

Certain material (indicated by three asterisks in brackets [***]) has been omitted from this document because it is both (1) not material and (2) would be competitively harmful if publicly disclosed.

Execution Copy

​

AMENDED AND RESTATED MASTER
SERVICES AGREEMENT

between

GRAND CANYON UNIVERSITY,
an Arizona nonprofit corporation

and

GRAND CANYON EDUCATION, INC.,
a Delaware corporation

​

​

​

1632486840.9


TABLE OF CONTENTS

Page No.

1.Definitions‌1

2.Certain Representations, Warranties and Covenants of the Parties‌1

3.Services Provided to University.‌1

3.1Services to be Provided; Exclusivity‌1

3.2Location of Services; Subcontracting‌2

3.3Services Addenda‌2

…

EX-10.2·10-Q·CIK 1434588·ACC 0001104659-26-088674·Filed Jul 30, 2026, 16:08 ET

EX-10.1

Healthcare Realty Trust Inc

SECOND AMENDMENT TO FIFTH AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT

THIS SECOND AMENDMENT TO FIFTH AMENDED AND RESTATED REVOLVING CREDIT AND TERM LOAN AGREEMENT (this “Amendment”) dated as of May 15, 2026 by and among HEALTHCARE REALTY HOLDINGS, L.P., a limited partnership formed under the laws of Delaware (the “Borrower”), HEALTHCARE REALTY TRUST INCORPORATED, a corporation formed under the laws of Maryland (“Parent”), each of the Lenders party hereto and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent (the “Administrative Agent”).

WHEREAS, the Borrower, Parent, the Lenders, the Administrative Agent and certain other parties have entered into that certain Fifth Amended and Restated Revolving Credit and Term Loan Agreement dated as of July 25, 2025 (as amended and as in effect immediately prior to the effectiveness of this Amendment, the “Existing Credit Agreement”); and

…

EX-10.1·10-Q·CIK 1360604·ACC 0001360604-26-000064·Filed Jul 30, 2026, 16:07 ET

EXHIBIT 10.1

FIRST SOLAR, INC.

Executive Performance Equity Plan

GRANT NOTICE

This Grant Notice sets forth the economic terms of a Performance Unit Award granted under the First Solar, Inc. 2020 Omnibus Incentive Compensation Plan (the “Plan”). This Grant Notice, together with the Performance Unit Award Agreement Form Perf Unit-018 (“Performance Unit Award Agreement”) (the terms of which are incorporated into this Grant Notice by reference), constitute the Award Agreement for this Performance Unit Award under the Executive Performance Equity Plan. Capitalized terms used in this Grant Notice that are not defined in this Grant Notice have the meanings as used or defined in the Performance Unit Award Agreement, or if not defined therein, the Plan. Additionally, the 2020 Omnibus Plan Prospectus is available for viewing on the First Solar POWER site.

…

EX-10.1·10-Q·CIK 1274494·ACC 0001274494-26-000170·Filed Jul 30, 2026, 16:06 ET

EX-10.1

PREFORMED LINE PRODUCTS CO

ANNEXNO.1

TOAGREEMENTNo.25/1095/INW/06FORANON-RENEWABLEINVESTMENTLOAN

Thepartiestothisannex,hereinafterreferredtoasthe“Annex,”are:

Bank Polska Kasa Opieki Spółka Akcyjna (trading as Bank Pekao S.A.), with its registered office in Warsaw, at ul. Żubra 1, postal code 01-066 (entered under KRS number: 0000014843 in the Register of Entrepreneurs maintained by the District Court for the Capital City of Warsaw in Warsaw, 13th Commercial Division of the National Court Register, subject to the supervision of the Polish Financial Supervision Authority, NIP: 526-000-68-41, REGON 000010205, share capital and paid-in capital: 262,470,034.00 zlotys), hereinafter referred to as the “Bank,” represented by two authorized representatives

and

…

EX-10.1·10-Q·CIK 80035·ACC 0000080035-26-000030·Filed Jul 30, 2026, 16:06 ET

EX-10.2

Fulcrum Therapeutics, Inc.

AMENDMENT TO EMPLOYMENT AGREEMENT

This is an amendment (the “Amendment”) to the Executive Employment Agreement dated May 12, 2023 (the “Agreement”) by and between Fulcrum Therapeutics, Inc. (the “Company”) and Alex Sapir (the “Executive”) (the Company and the Executive each a “Party” and together the “Parties”). This Amendment shall be effective on June 5, 2026 (the “Amendment EffectiveDate.”)

This Amendment supersedes any prior or contemporaneous agreement, communication or representation with, from or of the Company with respect to the terms described in this Amendment. Otherwise, with respect to all other terms, the Agreement remains in full force and effect. Capitalized but undefined terms in this Amendment are defined in the Agreement.

Executive’s Agreement is hereby amended as follows:

1.

A new Section 4(i) is hereby added to the Agreement, containing the following text:

…

EX-10.2·10-Q·CIK 1680581·ACC 0001193125-26-326098·Filed Jul 30, 2026, 16:05 ET

EX-10.1

Fulcrum Therapeutics, Inc.

April 27, 2026 Alan Musso

Dear Alan,

This letter summarizes the terms of the transition agreement that Fulcrum Therapeutics, Inc., (the “Company”) is willing to offer as a result of your voluntary retirement from the Company. Please read this letter agreement (the “Letter Agreement”), which includes a general release, carefully. If you are willing to agree to its terms, please sign in the space provided below and return it to me..

1.

If you do not sign this Letter Agreement within 21 days from receipt as dated above, your employment with the Company will end effective 21 days from the date of this Letter Agreement (“the Transition Date”). You will be paid for time worked through the Transition Date.

2.

…

EX-10.1·10-Q·CIK 1680581·ACC 0001193125-26-326098·Filed Jul 30, 2026, 16:05 ET

EX-10.4

Fulcrum Therapeutics, Inc.

AMENDMENT TO EMPLOYMENT AGREEMENT

This is an amendment (the “Amendment”) to the Executive Employment Agreement dated December 22, 2025 (the “Agreement”) by and between Fulcrum Therapeutics, Inc. (the “Company”) and Curt Oltmans (the “Executive”) (the Company and the Executive each a “Party” and together the “Parties”). This Amendment shall be effective on June 5, 2026 (the “AmendmentEffective Date.”)

This Amendment supersedes any prior or contemporaneous agreement, communication or representation with, from or of the Company with respect to the terms described in this Amendment. Otherwise, with respect to all other terms, the Agreement remains in full force and effect. Capitalized but undefined terms in this Amendment are defined in the Agreement.

Executive’s Agreement is hereby amended as follows:

1.

A new Section 4(h) is hereby added to the Agreement, containing the following text:

…

EX-10.4·10-Q·CIK 1680581·ACC 0001193125-26-326098·Filed Jul 30, 2026, 16:05 ET